RDHL
Redhill Biopharma Ltd
NASDAQ: RDHL · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$1.02
+3.00% today
Updated 2026-06-05
Market cap
$5.35M
P/E ratio
0.00
P/S ratio
18.70x
EPS (TTM)
$0.00
Dividend yield
—
52W range
$1 – $3
Volume
0.1M
Redhill Biopharma Ltd (RDHL) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$1.02
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.1B | $0.1B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -150.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.